The new dose of the protease inhibitor can be taken once daily as part of combination therapy, replacing two Reyataz 150 mg capsules.

"Bristol-Myers Squibb is committed to helping lead the development and production of innovative once-daily HIV medicines," said Wayne Quigley, president and general manager of Bristol-Myers Squibb Canada. "With the Reyataz 300 mg single-capsule formulation approval, Bristol-Myers Squibb now has one pill, once-daily HIV medicine option available in three drug classes, as part of combination therapy."

The company said it will continue to produce both the 150 mg and 200 mg formulations of Reyataz.